Featured BioVentrix® News

  • May 12, 2026

    BioVentrix® Names Carl Byrnes Chief Financial Officer

    91 German Hospitals Now Eligible to Negotiate Full Coverage for Revivent Therapy.

This page features official press releases from BioVentrix, highlighting key company announcements, clinical milestones, regulatory updates, and other developments relevant to our mission of advancing minimally invasive solutions for structural heart disease. These releases provide timely insight into our progress, partnerships, and commitment to improving patient outcomes through innovation.

Past Releases

  • March 26, 2026

    BioVentrix, Inc. Announces German Reimbursement Designation

    91 German Hospitals Now Eligible to Negotiate Full Coverage for Revivent Therapy.

  • November 3, 2025

    BioVentrix® Announces First Patient Treated with Revivent System in RELIVE Trial at Saint Luke’s Mid America Heart Institute

    Pivotal RELIVE Trial Is Evaluating the Safety and Efficacy of BioVentrix’s Revivent System in the Treatment of Patients Who Have Experienced Heart Failure

  • September 16, 2025

    BioVentrix Appoints Mark H. Ravich as Independent Board Member

    Seasoned Executive Brings Strategic Insight and Financial Expertise to Support Company’s Governance and Funding Initiatives.

  • September 10, 2025

    BioVentrix Appoints William T. Abraham, MD and Rishi Puri, MD, PhD, FRACP to Board of Directors

  • August 27, 2025

    BioVentrix® Names Vinod H. Thourani, MD and Marat Fudim, MD, MHS as National Co-Principal Investigators for its RELIVE Trial

  • January 21, 2025

    BioVentrix® Names Steven Chartier President and Co-Chief Executive Officer

  • April 13, 2023

    BioVentrix® Closes $48.5 Million Series A Financing

  • March 15, 2023

    New Study Demonstrates Accurate Measurement of Left Ventricular Function Following Treatment with BioVentrix Revivent TC® Therapy

    Inward Displacement Approach Assesses HFrEF Patients for Left Ventricular Device [...]

  • February 8, 2023

    BioVentrix Names Dr. Ori Ben-Yehuda as Chief Medical Officer

    Brings Extensive Clinical Trial and Patient Care Experience to Senior [...]

  • January 24, 2023

    FDA Agrees to Expanded Access Program for the BioVentrix Revivent TC® System for the Treatment of Ischemic Heart Failure

    Treatment IDE Will Provide Opportunity to Treat Additional Patients in [...]

  • January 27, 2022

    BioVentrix Expands Heart Failure Treatment Portfolio with Acquisition of MateraCor, Inc.

  • July 21, 2021

    BioVentrix Announces Raymond W. Cohen as Chairman of the Board and Newly Appointed Accredited Public Company Directors, Rinda K. Sama and Andrew G. Hinson to its Board of Directors

  • April 29, 2021

    BioVentrix Names Jim Dillon President and CEO

  • February 19, 2021

    Kardio-Tech-Firma aus Kalifornien gründet Deutschland-Niederlassung und macht so innovative Herztherapie breiter verfügbar

  • February 8, 2021

    BioVentrix Receives 2021 NUB Status 1 Reimbursement Renewal in Germany for the Revivent TC™ TransCatheter Ventricular Enhancement System

  • January 6, 2021

    BioVentrix Announces Jerry Estep, MD, as Co-Principal Investigator for ALIVE Pivotal Trial Studying a Transcatheter Device for Heart Failure

  • October 5, 2020

    BioVentrix Announces the Appointment of Cardiac Device Veteran Chris Wolff as Vice President of U.S. Sales

  • September 8, 2020

    Kasuistik zur Postinfarkt-Herzinsuffizienz publiziert

  • September 2, 2020

    BioVentrix Announces Pivotal ALIVE Trial Resumes with First Patients Treated with LIVE Therapy Since COVID-19 Pause

  • August 19, 2020

    BioVentrix Announces Appointment of Accredited Public Company Director, Raymond W. Cohen, to its Board of Directors

  • June 10, 2020

    Innovatives kathetergestütztes Verfahren, LIVE“ zur Behandlung der Herzschwäche nach Herzinfarkt

  • March 9, 2020

    FierceMedTech Names BioVentrix as One of Its “Fierce 15” Companies of 2019

  • March 4, 2020

    Dr. Ralph Stephan von Bardeleben als Co-Principal Investigator für die randomisierte klinische Studie REVIVE-HF von BioVentrix bekanntgegeben

  • March 3, 2020

    BioVentrix Announces Ralph Stephan von Bardeleben, MD, as Co- Principal Investigator of the REVIVE-HF Clinical Trial

  • February 18, 2020

    BioVentrix Announces Gregg Stone, MD, as Co-Principal Investigator for ALIVE Pivotal Trial of Transcatheter Device for Heart Failure

  • February 17, 2020

    Innovative Herzinfarkttherapie: Angebot in Deutschland wächst

  • February 6, 2020

    BioVentrix Receives 2020 NUB Reimbursement Status 1 Renewal in Germany for the Revivent TC™ TransCatheter Ventricular Enhancement System

  • January 22, 2020

    Europäische Kommission verlängert die CE-Zulassung für das BioVentrix Revivent TC System der LIVETM Therapie (Less Invasive Ventricular Enhancement)

  • January 21, 2020

    European Commission Grants BioVentrix CE Mark Extension for Revivent TC Less Invasive Ventricular Enhancement Therapy

  • December 3, 2019

    BioVentrix Announces Publication of Positive One-Year Outcomes for Revivent TC System

  • November 19, 2019

    FDA Grants Breakthrough Device Designation Status for BioVentrix Revivent TC Transcatheter Ventricular Enhancement System for Heart Failure

  • October 7, 2019

    BioVentrix Enrolls and Treats First Patient in REVIVE-HF European RCT for Ischemic Heart Failure Patients

  • September 23, 2019

    BioVentrix Announces Study Design for REVIVE-HF: Randomized Controlled Trial (RCT) in Europe

  • September 15, 2019

    BioVentrix Announces the Appointment of Pedro Marques as VP of Sales in Europe

  • August 5, 2019

    BioVentrix Announces Key Additions to Leadership Team

  • February 27, 2019

    BioVentrix Achieves 2019 NUB Reimbursement Status 1 in Germany for Revivent TC™ TransCatheter Ventricular Enhancement System

  • March 12, 2018

    BioVentrix Announces First Patient at Cardiovascular Institute of the South Successfully Treated in IDE Study of Revivent TC™ TransCatheter Ventricular Enhancement Treatment

  • February 6, 2018

    BioVentrix Achieves 2018 NUB Reimbursement Status 1 in Germany for Revivent TC™ TransCatheter Ventricular Enhancement System

  • April 17, 2017

    BioVentrix announces the 1st image fusion-guided Revivent TC™ TransCatheter Ventricular Enhancement procedure for treating Ischemic Cardiomyopathy

  • March 13, 2017

    BioVentrix announces the 1st Revivent TC™ TransCatheter commercial procedure to Treat Ischemic Cardiomyopathy in China

  • February 6, 2017

    BioVentrix Announces NUB Reimbursement Status 1 for Revivent TC™ TransCatheter Ventricular Enhancement System in Germany

  • December 19, 2016

    BioVentrix announces the 1st Revivent TC™ TransCatheter Ventricular Enhancement procedure in Germany after receiving CE-Mark Certification

  • November 21, 2016

    BioVentrix announces the 1st Revivent TC™ TransCatheter Ventricular Enhancement procedure for Ischemic Cardiomyopathy treatment in the Netherlands

  • October 4, 2016

    Steven Healy appointed as Chairman of the Board of Directors of BioVentrix, Inc.

  • June 27, 2016

    BioVentrix Receives CE Marking Certification for Revivent TC™, the First Minimally Invasive Heart Failure Treatment to Restore the Left Ventricle

  • May 31, 2016

    BioVentrix receives FDA IDE Approval for its Pivotal Clinical Trial, ALIVE

  • May 16, 2016

    BioVentrix Announces Successful First-In-Man, Catheter-Based Endovascular Clinical Procedure with Revivent-TC™ System for Heart Failure Treatment